Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SOX17 enables immune evasion of early colorectal adenomas and cancers.
Goto N, Westcott PMK, Goto S, Imada S, Taylor MS, Eng G, Braverman J, Deshpande V, Jacks T, Agudo J, Yilmaz ÖH. Goto N, et al. Among authors: braverman j. Nature. 2024 Mar;627(8004):636-645. doi: 10.1038/s41586-024-07135-3. Epub 2024 Feb 28. Nature. 2024. PMID: 38418875
Administering selected subscales of patient-reported outcome questionnaires to reduce patient burden and increase relevance: a position statement on a modular approach.
Serrano D, Cella D, Husereau D, King-Kallimanis B, Mendoza T, Salmonson T, Stone A, Zaleta A, Dhanda D, Moshyk A, Liu F, Shields AL, Taylor F, Spite S, Shaw JW, Braverman J. Serrano D, et al. Among authors: braverman j. Qual Life Res. 2024 Apr;33(4):1075-1084. doi: 10.1007/s11136-023-03587-8. Epub 2024 Jan 24. Qual Life Res. 2024. PMID: 38265747 Free PMC article.
Supporting the democratization of science during a pandemic: genomics Course-based Undergraduate Research Experiences (CUREs) as an effective remote learning strategy.
Lopatto D, Silver Key SC, Van Stry M, Siders J, Leung W, Sandlin KM, Rele CP; Genomics Education Partnership; Reed LK. Lopatto D, et al. J Microbiol Biol Educ. 2023 Sep 22;24(3):e00039-23. doi: 10.1128/jmbe.00039-23. eCollection 2023 Dec. J Microbiol Biol Educ. 2023. PMID: 38230306 Free PMC article.
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma.
Rodríguez Otero P, Towle K, Cope S, Caisip C, Davies FE, Delforge M, Weisel K, Marshall TS, Karampampa K, Ayers D, Mojebi A, Braverman J, Farrell J, Dhanda D. Rodríguez Otero P, et al. Among authors: braverman j. Leuk Lymphoma. 2023 Nov-Dec;64(11):1864-1869. doi: 10.1080/10428194.2023.2235042. Epub 2023 Jul 27. Leuk Lymphoma. 2023. PMID: 37497883 No abstract available.
Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial.
Delforge M, Otero PR, Shah N, Moshkovich O, Braverman J, Dhanda DS, Lanar S, Devlen J, Miera M, Gerould H, Campbell TB, Munshi NC. Delforge M, et al. Among authors: braverman j. Leuk Res. 2023 Jun;129:107074. doi: 10.1016/j.leukres.2023.107074. Epub 2023 Apr 3. Leuk Res. 2023. PMID: 37087950 Free article. Clinical Trial.
111 results